2026 Ovarian Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Glioblastoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Advanced Melanoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

Anagliptin/Empagliflozin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

2026 Clear Cell Renal Cell Carcinoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…

2026 Metastatic Castration-Resistant Prostate Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and…

2026 Biliary Tract Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Hepatocellular Carcinoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Gastric and GEJ Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 Pancreatic Ductal Adenocarcinoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…

2026 Metastatic Colorectal Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…

2026 HR-Positive Breast Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…